BSG and hepatocellular carcinoma: Treatment of human hepatocellular carcinoma (Huh-7) cells with anti-CD147 ILs-DOX resulted in a significant reduction in CD133-positive cancer stem cells compared to unmodified PLD, demonstrating the possibility of anti-CD147 ILs-DOX to target liver cancer stem cells.